J CLIN ENDOCR METAB 润色咨询

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

出版年份:1952 年文章数:15441 投稿命中率: 开通期刊会员,数据随心看

出版周期:Monthly 自引率:4.0% 审稿周期: 开通期刊会员,数据随心看

前往期刊查询

期刊讨论

  1. [GetPortalCommentsPageByObjectIdResponse(id=2195585, encodeId=5f702195585d8, content=审稿速度:3.0 | 投稿命中率:25.0<br>经验分享:3月18日 投稿,到现在 一直是 Manuscript Submitted!什么情况,我看着大家的速度都挺快啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=7b725453206, createdName=ms8000000183026287, createdTime=Wed Mar 27 06:41:54 CST 2024, time=2024-03-27, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2183773, encodeId=0a5a2183e7317, content=不能提供中文的伦理,不懂怎么搞, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b1668197286, createdName=ms6000000741257643, createdTime=Wed Jan 24 23:26:21 CST 2024, time=2024-01-24, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2182073, encodeId=9c2d21820e320, content=审稿速度:1.0<br>偏重的研究方向:代谢内分泌<br>经验分享:1.9号投的稿,已经过去7天了,一直在with editor的状态。想请教各位大佬何时才会under review呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5d4b8504046, createdName=ms8000001820221539, createdTime=Tue Jan 16 21:41:20 CST 2024, time=2024-01-16, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2144472, encodeId=076121444e2ef, content=第一天投稿,第二天under review,第四天with editor。。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=171, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230102/946f899161a14c3dbe77c26d05ba17d8/114975187bd54951beda40eaafd6f34e.jpg, createdBy=59ae5404963, createdName=MedSci_007, createdTime=Sat Jun 24 09:58:02 CST 2023, time=2023-06-24, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2165427, encodeId=86f3216542ea7, content=为什么回顾性研究也邮件让我发provide the Institutional Review Board or ethical review board’s approval/exemption letter,我明明文章中已经提到which waived the requirement for informed consent because of the retrospective nature of this study啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=82, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e43b5476402, createdName=ms4000001768031770, createdTime=Sat Oct 28 16:07:09 CST 2023, time=2023-10-28, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1241105, encodeId=c8d0124110569, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向:心血管;糖尿病<br>经验分享:记录一下,第一个SCI:5月10日投稿的,大约5天内就被under review被送审了。一个月后返回。修稿一个月后,两周就接受啦。审稿速度非常可!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=396, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=35e75613536, createdName=ms5000000174582530, createdTime=Fri Aug 26 09:43:34 CST 2022, time=2022-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=944787, encodeId=ab53944e87d6, content=2020.09.22投稿,一审3个月,催稿问了下,说是前两个审稿人意见有分歧,所以邀请了第三个审稿人;返回大修2个月;2021.02.04再投,目前with editor了,希望能接收,祈祷, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=682, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLFHmdHZlP01VibUiaSUygPr1vfgUOicNUzicicuib25U9FM5WbtwPBfX6diaZbduz72Vjf0KFc8TINLKKvA/132, createdBy=d1062255989, createdName=延光星辰, createdTime=Tue Mar 02 14:31:35 CST 2021, time=2021-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1187926, encodeId=a5d4118e92666, content=审稿速度:2.0<br>偏重的研究方向:心血管<br>经验分享:记录一下第一篇SCI:10/30/2021Submitted, 12/07/2021Revise, 01/04/2022Revise manuscript submitted, 01/13/2022Revise, 01/24/2022Accept<br>稿件处理速度可以,投稿后很快就Under review了,意见回来是major revision,两个审稿人在领域内比较专业,提了一大堆意见,花了近一个月时间才修好稿件,提交后面又经历了两次小修,意见回的很快,最后接收。<br>Revise后提交稿件要求Supplementary文件上传公共数据库并在文中引用,Manuscript里不能带有Supplementary图表的信息。Revise给的时间是3个月,还是很充裕的。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1261, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d5e05514512, createdName=陈呦呦, createdTime=Tue Jan 25 08:40:28 CST 2022, time=2022-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2156082, encodeId=856a215608284, content=为什么 投稿过程老是提示Additional information未完成呢?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=155, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=08398439451, createdName=ms3000001792867707, createdTime=Mon Sep 04 20:45:57 CST 2023, time=2023-09-04, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=1073628, encodeId=bf4b10e3628d6, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向:心血管代谢<br>经验分享:一审一个月,2个审稿人,给的意见都很不错,修回编辑直接决定接收了,文章如果比较新颖,故事说的也比较完整还是很有希望的!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1291, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=95512077050, createdName=1321f15a85m, createdTime=Wed Nov 24 20:49:29 CST 2021, time=2021-11-24, status=1, ipAttribution=)]
    2024-03-27 ms8000000183026287 来自山东省

    审稿速度:3.0 | 投稿命中率:25.0
    经验分享:3月18日 投稿,到现在 一直是 Manuscript Submitted!什么情况,我看着大家的速度都挺快啊

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=2195585, encodeId=5f702195585d8, content=审稿速度:3.0 | 投稿命中率:25.0<br>经验分享:3月18日 投稿,到现在 一直是 Manuscript Submitted!什么情况,我看着大家的速度都挺快啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=7b725453206, createdName=ms8000000183026287, createdTime=Wed Mar 27 06:41:54 CST 2024, time=2024-03-27, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2183773, encodeId=0a5a2183e7317, content=不能提供中文的伦理,不懂怎么搞, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b1668197286, createdName=ms6000000741257643, createdTime=Wed Jan 24 23:26:21 CST 2024, time=2024-01-24, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2182073, encodeId=9c2d21820e320, content=审稿速度:1.0<br>偏重的研究方向:代谢内分泌<br>经验分享:1.9号投的稿,已经过去7天了,一直在with editor的状态。想请教各位大佬何时才会under review呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5d4b8504046, createdName=ms8000001820221539, createdTime=Tue Jan 16 21:41:20 CST 2024, time=2024-01-16, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2144472, encodeId=076121444e2ef, content=第一天投稿,第二天under review,第四天with editor。。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=171, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230102/946f899161a14c3dbe77c26d05ba17d8/114975187bd54951beda40eaafd6f34e.jpg, createdBy=59ae5404963, createdName=MedSci_007, createdTime=Sat Jun 24 09:58:02 CST 2023, time=2023-06-24, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2165427, encodeId=86f3216542ea7, content=为什么回顾性研究也邮件让我发provide the Institutional Review Board or ethical review board’s approval/exemption letter,我明明文章中已经提到which waived the requirement for informed consent because of the retrospective nature of this study啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=82, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e43b5476402, createdName=ms4000001768031770, createdTime=Sat Oct 28 16:07:09 CST 2023, time=2023-10-28, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1241105, encodeId=c8d0124110569, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向:心血管;糖尿病<br>经验分享:记录一下,第一个SCI:5月10日投稿的,大约5天内就被under review被送审了。一个月后返回。修稿一个月后,两周就接受啦。审稿速度非常可!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=396, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=35e75613536, createdName=ms5000000174582530, createdTime=Fri Aug 26 09:43:34 CST 2022, time=2022-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=944787, encodeId=ab53944e87d6, content=2020.09.22投稿,一审3个月,催稿问了下,说是前两个审稿人意见有分歧,所以邀请了第三个审稿人;返回大修2个月;2021.02.04再投,目前with editor了,希望能接收,祈祷, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=682, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLFHmdHZlP01VibUiaSUygPr1vfgUOicNUzicicuib25U9FM5WbtwPBfX6diaZbduz72Vjf0KFc8TINLKKvA/132, createdBy=d1062255989, createdName=延光星辰, createdTime=Tue Mar 02 14:31:35 CST 2021, time=2021-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1187926, encodeId=a5d4118e92666, content=审稿速度:2.0<br>偏重的研究方向:心血管<br>经验分享:记录一下第一篇SCI:10/30/2021Submitted, 12/07/2021Revise, 01/04/2022Revise manuscript submitted, 01/13/2022Revise, 01/24/2022Accept<br>稿件处理速度可以,投稿后很快就Under review了,意见回来是major revision,两个审稿人在领域内比较专业,提了一大堆意见,花了近一个月时间才修好稿件,提交后面又经历了两次小修,意见回的很快,最后接收。<br>Revise后提交稿件要求Supplementary文件上传公共数据库并在文中引用,Manuscript里不能带有Supplementary图表的信息。Revise给的时间是3个月,还是很充裕的。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1261, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d5e05514512, createdName=陈呦呦, createdTime=Tue Jan 25 08:40:28 CST 2022, time=2022-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2156082, encodeId=856a215608284, content=为什么 投稿过程老是提示Additional information未完成呢?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=155, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=08398439451, createdName=ms3000001792867707, createdTime=Mon Sep 04 20:45:57 CST 2023, time=2023-09-04, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=1073628, encodeId=bf4b10e3628d6, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向:心血管代谢<br>经验分享:一审一个月,2个审稿人,给的意见都很不错,修回编辑直接决定接收了,文章如果比较新颖,故事说的也比较完整还是很有希望的!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1291, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=95512077050, createdName=1321f15a85m, createdTime=Wed Nov 24 20:49:29 CST 2021, time=2021-11-24, status=1, ipAttribution=)]
    2024-01-24 ms6000000741257643 来自广西

    不能提供中文的伦理,不懂怎么搞

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2195585, encodeId=5f702195585d8, content=审稿速度:3.0 | 投稿命中率:25.0<br>经验分享:3月18日 投稿,到现在 一直是 Manuscript Submitted!什么情况,我看着大家的速度都挺快啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=7b725453206, createdName=ms8000000183026287, createdTime=Wed Mar 27 06:41:54 CST 2024, time=2024-03-27, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2183773, encodeId=0a5a2183e7317, content=不能提供中文的伦理,不懂怎么搞, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b1668197286, createdName=ms6000000741257643, createdTime=Wed Jan 24 23:26:21 CST 2024, time=2024-01-24, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2182073, encodeId=9c2d21820e320, content=审稿速度:1.0<br>偏重的研究方向:代谢内分泌<br>经验分享:1.9号投的稿,已经过去7天了,一直在with editor的状态。想请教各位大佬何时才会under review呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5d4b8504046, createdName=ms8000001820221539, createdTime=Tue Jan 16 21:41:20 CST 2024, time=2024-01-16, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2144472, encodeId=076121444e2ef, content=第一天投稿,第二天under review,第四天with editor。。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=171, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230102/946f899161a14c3dbe77c26d05ba17d8/114975187bd54951beda40eaafd6f34e.jpg, createdBy=59ae5404963, createdName=MedSci_007, createdTime=Sat Jun 24 09:58:02 CST 2023, time=2023-06-24, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2165427, encodeId=86f3216542ea7, content=为什么回顾性研究也邮件让我发provide the Institutional Review Board or ethical review board’s approval/exemption letter,我明明文章中已经提到which waived the requirement for informed consent because of the retrospective nature of this study啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=82, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e43b5476402, createdName=ms4000001768031770, createdTime=Sat Oct 28 16:07:09 CST 2023, time=2023-10-28, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1241105, encodeId=c8d0124110569, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向:心血管;糖尿病<br>经验分享:记录一下,第一个SCI:5月10日投稿的,大约5天内就被under review被送审了。一个月后返回。修稿一个月后,两周就接受啦。审稿速度非常可!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=396, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=35e75613536, createdName=ms5000000174582530, createdTime=Fri Aug 26 09:43:34 CST 2022, time=2022-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=944787, encodeId=ab53944e87d6, content=2020.09.22投稿,一审3个月,催稿问了下,说是前两个审稿人意见有分歧,所以邀请了第三个审稿人;返回大修2个月;2021.02.04再投,目前with editor了,希望能接收,祈祷, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=682, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLFHmdHZlP01VibUiaSUygPr1vfgUOicNUzicicuib25U9FM5WbtwPBfX6diaZbduz72Vjf0KFc8TINLKKvA/132, createdBy=d1062255989, createdName=延光星辰, createdTime=Tue Mar 02 14:31:35 CST 2021, time=2021-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1187926, encodeId=a5d4118e92666, content=审稿速度:2.0<br>偏重的研究方向:心血管<br>经验分享:记录一下第一篇SCI:10/30/2021Submitted, 12/07/2021Revise, 01/04/2022Revise manuscript submitted, 01/13/2022Revise, 01/24/2022Accept<br>稿件处理速度可以,投稿后很快就Under review了,意见回来是major revision,两个审稿人在领域内比较专业,提了一大堆意见,花了近一个月时间才修好稿件,提交后面又经历了两次小修,意见回的很快,最后接收。<br>Revise后提交稿件要求Supplementary文件上传公共数据库并在文中引用,Manuscript里不能带有Supplementary图表的信息。Revise给的时间是3个月,还是很充裕的。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1261, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d5e05514512, createdName=陈呦呦, createdTime=Tue Jan 25 08:40:28 CST 2022, time=2022-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2156082, encodeId=856a215608284, content=为什么 投稿过程老是提示Additional information未完成呢?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=155, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=08398439451, createdName=ms3000001792867707, createdTime=Mon Sep 04 20:45:57 CST 2023, time=2023-09-04, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=1073628, encodeId=bf4b10e3628d6, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向:心血管代谢<br>经验分享:一审一个月,2个审稿人,给的意见都很不错,修回编辑直接决定接收了,文章如果比较新颖,故事说的也比较完整还是很有希望的!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1291, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=95512077050, createdName=1321f15a85m, createdTime=Wed Nov 24 20:49:29 CST 2021, time=2021-11-24, status=1, ipAttribution=)]
    2024-01-16 ms8000001820221539 来自湖南省

    审稿速度:1.0
    偏重的研究方向:代谢内分泌
    经验分享:1.9号投的稿,已经过去7天了,一直在with editor的状态。想请教各位大佬何时才会under review呀

    1

    展开1条回复
  4. [GetPortalCommentsPageByObjectIdResponse(id=2195585, encodeId=5f702195585d8, content=审稿速度:3.0 | 投稿命中率:25.0<br>经验分享:3月18日 投稿,到现在 一直是 Manuscript Submitted!什么情况,我看着大家的速度都挺快啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=7b725453206, createdName=ms8000000183026287, createdTime=Wed Mar 27 06:41:54 CST 2024, time=2024-03-27, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2183773, encodeId=0a5a2183e7317, content=不能提供中文的伦理,不懂怎么搞, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b1668197286, createdName=ms6000000741257643, createdTime=Wed Jan 24 23:26:21 CST 2024, time=2024-01-24, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2182073, encodeId=9c2d21820e320, content=审稿速度:1.0<br>偏重的研究方向:代谢内分泌<br>经验分享:1.9号投的稿,已经过去7天了,一直在with editor的状态。想请教各位大佬何时才会under review呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5d4b8504046, createdName=ms8000001820221539, createdTime=Tue Jan 16 21:41:20 CST 2024, time=2024-01-16, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2144472, encodeId=076121444e2ef, content=第一天投稿,第二天under review,第四天with editor。。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=171, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230102/946f899161a14c3dbe77c26d05ba17d8/114975187bd54951beda40eaafd6f34e.jpg, createdBy=59ae5404963, createdName=MedSci_007, createdTime=Sat Jun 24 09:58:02 CST 2023, time=2023-06-24, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2165427, encodeId=86f3216542ea7, content=为什么回顾性研究也邮件让我发provide the Institutional Review Board or ethical review board’s approval/exemption letter,我明明文章中已经提到which waived the requirement for informed consent because of the retrospective nature of this study啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=82, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e43b5476402, createdName=ms4000001768031770, createdTime=Sat Oct 28 16:07:09 CST 2023, time=2023-10-28, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1241105, encodeId=c8d0124110569, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向:心血管;糖尿病<br>经验分享:记录一下,第一个SCI:5月10日投稿的,大约5天内就被under review被送审了。一个月后返回。修稿一个月后,两周就接受啦。审稿速度非常可!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=396, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=35e75613536, createdName=ms5000000174582530, createdTime=Fri Aug 26 09:43:34 CST 2022, time=2022-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=944787, encodeId=ab53944e87d6, content=2020.09.22投稿,一审3个月,催稿问了下,说是前两个审稿人意见有分歧,所以邀请了第三个审稿人;返回大修2个月;2021.02.04再投,目前with editor了,希望能接收,祈祷, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=682, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLFHmdHZlP01VibUiaSUygPr1vfgUOicNUzicicuib25U9FM5WbtwPBfX6diaZbduz72Vjf0KFc8TINLKKvA/132, createdBy=d1062255989, createdName=延光星辰, createdTime=Tue Mar 02 14:31:35 CST 2021, time=2021-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1187926, encodeId=a5d4118e92666, content=审稿速度:2.0<br>偏重的研究方向:心血管<br>经验分享:记录一下第一篇SCI:10/30/2021Submitted, 12/07/2021Revise, 01/04/2022Revise manuscript submitted, 01/13/2022Revise, 01/24/2022Accept<br>稿件处理速度可以,投稿后很快就Under review了,意见回来是major revision,两个审稿人在领域内比较专业,提了一大堆意见,花了近一个月时间才修好稿件,提交后面又经历了两次小修,意见回的很快,最后接收。<br>Revise后提交稿件要求Supplementary文件上传公共数据库并在文中引用,Manuscript里不能带有Supplementary图表的信息。Revise给的时间是3个月,还是很充裕的。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1261, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d5e05514512, createdName=陈呦呦, createdTime=Tue Jan 25 08:40:28 CST 2022, time=2022-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2156082, encodeId=856a215608284, content=为什么 投稿过程老是提示Additional information未完成呢?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=155, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=08398439451, createdName=ms3000001792867707, createdTime=Mon Sep 04 20:45:57 CST 2023, time=2023-09-04, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=1073628, encodeId=bf4b10e3628d6, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向:心血管代谢<br>经验分享:一审一个月,2个审稿人,给的意见都很不错,修回编辑直接决定接收了,文章如果比较新颖,故事说的也比较完整还是很有希望的!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1291, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=95512077050, createdName=1321f15a85m, createdTime=Wed Nov 24 20:49:29 CST 2021, time=2021-11-24, status=1, ipAttribution=)]
    2023-06-24 MedSci_007 来自吉林省

    第一天投稿,第二天under review,第四天with editor。。。。

    8

    展开8条回复
  5. [GetPortalCommentsPageByObjectIdResponse(id=2195585, encodeId=5f702195585d8, content=审稿速度:3.0 | 投稿命中率:25.0<br>经验分享:3月18日 投稿,到现在 一直是 Manuscript Submitted!什么情况,我看着大家的速度都挺快啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=7b725453206, createdName=ms8000000183026287, createdTime=Wed Mar 27 06:41:54 CST 2024, time=2024-03-27, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2183773, encodeId=0a5a2183e7317, content=不能提供中文的伦理,不懂怎么搞, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b1668197286, createdName=ms6000000741257643, createdTime=Wed Jan 24 23:26:21 CST 2024, time=2024-01-24, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2182073, encodeId=9c2d21820e320, content=审稿速度:1.0<br>偏重的研究方向:代谢内分泌<br>经验分享:1.9号投的稿,已经过去7天了,一直在with editor的状态。想请教各位大佬何时才会under review呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5d4b8504046, createdName=ms8000001820221539, createdTime=Tue Jan 16 21:41:20 CST 2024, time=2024-01-16, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2144472, encodeId=076121444e2ef, content=第一天投稿,第二天under review,第四天with editor。。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=171, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230102/946f899161a14c3dbe77c26d05ba17d8/114975187bd54951beda40eaafd6f34e.jpg, createdBy=59ae5404963, createdName=MedSci_007, createdTime=Sat Jun 24 09:58:02 CST 2023, time=2023-06-24, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2165427, encodeId=86f3216542ea7, content=为什么回顾性研究也邮件让我发provide the Institutional Review Board or ethical review board’s approval/exemption letter,我明明文章中已经提到which waived the requirement for informed consent because of the retrospective nature of this study啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=82, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e43b5476402, createdName=ms4000001768031770, createdTime=Sat Oct 28 16:07:09 CST 2023, time=2023-10-28, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1241105, encodeId=c8d0124110569, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向:心血管;糖尿病<br>经验分享:记录一下,第一个SCI:5月10日投稿的,大约5天内就被under review被送审了。一个月后返回。修稿一个月后,两周就接受啦。审稿速度非常可!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=396, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=35e75613536, createdName=ms5000000174582530, createdTime=Fri Aug 26 09:43:34 CST 2022, time=2022-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=944787, encodeId=ab53944e87d6, content=2020.09.22投稿,一审3个月,催稿问了下,说是前两个审稿人意见有分歧,所以邀请了第三个审稿人;返回大修2个月;2021.02.04再投,目前with editor了,希望能接收,祈祷, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=682, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLFHmdHZlP01VibUiaSUygPr1vfgUOicNUzicicuib25U9FM5WbtwPBfX6diaZbduz72Vjf0KFc8TINLKKvA/132, createdBy=d1062255989, createdName=延光星辰, createdTime=Tue Mar 02 14:31:35 CST 2021, time=2021-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1187926, encodeId=a5d4118e92666, content=审稿速度:2.0<br>偏重的研究方向:心血管<br>经验分享:记录一下第一篇SCI:10/30/2021Submitted, 12/07/2021Revise, 01/04/2022Revise manuscript submitted, 01/13/2022Revise, 01/24/2022Accept<br>稿件处理速度可以,投稿后很快就Under review了,意见回来是major revision,两个审稿人在领域内比较专业,提了一大堆意见,花了近一个月时间才修好稿件,提交后面又经历了两次小修,意见回的很快,最后接收。<br>Revise后提交稿件要求Supplementary文件上传公共数据库并在文中引用,Manuscript里不能带有Supplementary图表的信息。Revise给的时间是3个月,还是很充裕的。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1261, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d5e05514512, createdName=陈呦呦, createdTime=Tue Jan 25 08:40:28 CST 2022, time=2022-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2156082, encodeId=856a215608284, content=为什么 投稿过程老是提示Additional information未完成呢?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=155, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=08398439451, createdName=ms3000001792867707, createdTime=Mon Sep 04 20:45:57 CST 2023, time=2023-09-04, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=1073628, encodeId=bf4b10e3628d6, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向:心血管代谢<br>经验分享:一审一个月,2个审稿人,给的意见都很不错,修回编辑直接决定接收了,文章如果比较新颖,故事说的也比较完整还是很有希望的!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1291, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=95512077050, createdName=1321f15a85m, createdTime=Wed Nov 24 20:49:29 CST 2021, time=2021-11-24, status=1, ipAttribution=)]
    2023-10-28 ms4000001768031770 来自广东省

    为什么回顾性研究也邮件让我发provide the Institutional Review Board or ethical review board’s approval/exemption letter,我明明文章中已经提到which waived the requirement for informed consent because of the retrospective nature of this study啊

    3

    展开3条回复
  6. [GetPortalCommentsPageByObjectIdResponse(id=2195585, encodeId=5f702195585d8, content=审稿速度:3.0 | 投稿命中率:25.0<br>经验分享:3月18日 投稿,到现在 一直是 Manuscript Submitted!什么情况,我看着大家的速度都挺快啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=7b725453206, createdName=ms8000000183026287, createdTime=Wed Mar 27 06:41:54 CST 2024, time=2024-03-27, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2183773, encodeId=0a5a2183e7317, content=不能提供中文的伦理,不懂怎么搞, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b1668197286, createdName=ms6000000741257643, createdTime=Wed Jan 24 23:26:21 CST 2024, time=2024-01-24, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2182073, encodeId=9c2d21820e320, content=审稿速度:1.0<br>偏重的研究方向:代谢内分泌<br>经验分享:1.9号投的稿,已经过去7天了,一直在with editor的状态。想请教各位大佬何时才会under review呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5d4b8504046, createdName=ms8000001820221539, createdTime=Tue Jan 16 21:41:20 CST 2024, time=2024-01-16, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2144472, encodeId=076121444e2ef, content=第一天投稿,第二天under review,第四天with editor。。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=171, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230102/946f899161a14c3dbe77c26d05ba17d8/114975187bd54951beda40eaafd6f34e.jpg, createdBy=59ae5404963, createdName=MedSci_007, createdTime=Sat Jun 24 09:58:02 CST 2023, time=2023-06-24, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2165427, encodeId=86f3216542ea7, content=为什么回顾性研究也邮件让我发provide the Institutional Review Board or ethical review board’s approval/exemption letter,我明明文章中已经提到which waived the requirement for informed consent because of the retrospective nature of this study啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=82, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e43b5476402, createdName=ms4000001768031770, createdTime=Sat Oct 28 16:07:09 CST 2023, time=2023-10-28, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1241105, encodeId=c8d0124110569, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向:心血管;糖尿病<br>经验分享:记录一下,第一个SCI:5月10日投稿的,大约5天内就被under review被送审了。一个月后返回。修稿一个月后,两周就接受啦。审稿速度非常可!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=396, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=35e75613536, createdName=ms5000000174582530, createdTime=Fri Aug 26 09:43:34 CST 2022, time=2022-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=944787, encodeId=ab53944e87d6, content=2020.09.22投稿,一审3个月,催稿问了下,说是前两个审稿人意见有分歧,所以邀请了第三个审稿人;返回大修2个月;2021.02.04再投,目前with editor了,希望能接收,祈祷, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=682, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLFHmdHZlP01VibUiaSUygPr1vfgUOicNUzicicuib25U9FM5WbtwPBfX6diaZbduz72Vjf0KFc8TINLKKvA/132, createdBy=d1062255989, createdName=延光星辰, createdTime=Tue Mar 02 14:31:35 CST 2021, time=2021-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1187926, encodeId=a5d4118e92666, content=审稿速度:2.0<br>偏重的研究方向:心血管<br>经验分享:记录一下第一篇SCI:10/30/2021Submitted, 12/07/2021Revise, 01/04/2022Revise manuscript submitted, 01/13/2022Revise, 01/24/2022Accept<br>稿件处理速度可以,投稿后很快就Under review了,意见回来是major revision,两个审稿人在领域内比较专业,提了一大堆意见,花了近一个月时间才修好稿件,提交后面又经历了两次小修,意见回的很快,最后接收。<br>Revise后提交稿件要求Supplementary文件上传公共数据库并在文中引用,Manuscript里不能带有Supplementary图表的信息。Revise给的时间是3个月,还是很充裕的。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1261, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d5e05514512, createdName=陈呦呦, createdTime=Tue Jan 25 08:40:28 CST 2022, time=2022-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2156082, encodeId=856a215608284, content=为什么 投稿过程老是提示Additional information未完成呢?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=155, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=08398439451, createdName=ms3000001792867707, createdTime=Mon Sep 04 20:45:57 CST 2023, time=2023-09-04, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=1073628, encodeId=bf4b10e3628d6, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向:心血管代谢<br>经验分享:一审一个月,2个审稿人,给的意见都很不错,修回编辑直接决定接收了,文章如果比较新颖,故事说的也比较完整还是很有希望的!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1291, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=95512077050, createdName=1321f15a85m, createdTime=Wed Nov 24 20:49:29 CST 2021, time=2021-11-24, status=1, ipAttribution=)]
    2022-08-26 ms5000000174582530

    审稿速度:1.0 | 投稿命中率:50.0
    偏重的研究方向:心血管;糖尿病
    经验分享:记录一下,第一个SCI:5月10日投稿的,大约5天内就被under review被送审了。一个月后返回。修稿一个月后,两周就接受啦。审稿速度非常可!

    10

    展开10条回复
  7. [GetPortalCommentsPageByObjectIdResponse(id=2195585, encodeId=5f702195585d8, content=审稿速度:3.0 | 投稿命中率:25.0<br>经验分享:3月18日 投稿,到现在 一直是 Manuscript Submitted!什么情况,我看着大家的速度都挺快啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=7b725453206, createdName=ms8000000183026287, createdTime=Wed Mar 27 06:41:54 CST 2024, time=2024-03-27, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2183773, encodeId=0a5a2183e7317, content=不能提供中文的伦理,不懂怎么搞, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b1668197286, createdName=ms6000000741257643, createdTime=Wed Jan 24 23:26:21 CST 2024, time=2024-01-24, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2182073, encodeId=9c2d21820e320, content=审稿速度:1.0<br>偏重的研究方向:代谢内分泌<br>经验分享:1.9号投的稿,已经过去7天了,一直在with editor的状态。想请教各位大佬何时才会under review呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5d4b8504046, createdName=ms8000001820221539, createdTime=Tue Jan 16 21:41:20 CST 2024, time=2024-01-16, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2144472, encodeId=076121444e2ef, content=第一天投稿,第二天under review,第四天with editor。。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=171, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230102/946f899161a14c3dbe77c26d05ba17d8/114975187bd54951beda40eaafd6f34e.jpg, createdBy=59ae5404963, createdName=MedSci_007, createdTime=Sat Jun 24 09:58:02 CST 2023, time=2023-06-24, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2165427, encodeId=86f3216542ea7, content=为什么回顾性研究也邮件让我发provide the Institutional Review Board or ethical review board’s approval/exemption letter,我明明文章中已经提到which waived the requirement for informed consent because of the retrospective nature of this study啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=82, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e43b5476402, createdName=ms4000001768031770, createdTime=Sat Oct 28 16:07:09 CST 2023, time=2023-10-28, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1241105, encodeId=c8d0124110569, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向:心血管;糖尿病<br>经验分享:记录一下,第一个SCI:5月10日投稿的,大约5天内就被under review被送审了。一个月后返回。修稿一个月后,两周就接受啦。审稿速度非常可!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=396, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=35e75613536, createdName=ms5000000174582530, createdTime=Fri Aug 26 09:43:34 CST 2022, time=2022-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=944787, encodeId=ab53944e87d6, content=2020.09.22投稿,一审3个月,催稿问了下,说是前两个审稿人意见有分歧,所以邀请了第三个审稿人;返回大修2个月;2021.02.04再投,目前with editor了,希望能接收,祈祷, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=682, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLFHmdHZlP01VibUiaSUygPr1vfgUOicNUzicicuib25U9FM5WbtwPBfX6diaZbduz72Vjf0KFc8TINLKKvA/132, createdBy=d1062255989, createdName=延光星辰, createdTime=Tue Mar 02 14:31:35 CST 2021, time=2021-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1187926, encodeId=a5d4118e92666, content=审稿速度:2.0<br>偏重的研究方向:心血管<br>经验分享:记录一下第一篇SCI:10/30/2021Submitted, 12/07/2021Revise, 01/04/2022Revise manuscript submitted, 01/13/2022Revise, 01/24/2022Accept<br>稿件处理速度可以,投稿后很快就Under review了,意见回来是major revision,两个审稿人在领域内比较专业,提了一大堆意见,花了近一个月时间才修好稿件,提交后面又经历了两次小修,意见回的很快,最后接收。<br>Revise后提交稿件要求Supplementary文件上传公共数据库并在文中引用,Manuscript里不能带有Supplementary图表的信息。Revise给的时间是3个月,还是很充裕的。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1261, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d5e05514512, createdName=陈呦呦, createdTime=Tue Jan 25 08:40:28 CST 2022, time=2022-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2156082, encodeId=856a215608284, content=为什么 投稿过程老是提示Additional information未完成呢?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=155, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=08398439451, createdName=ms3000001792867707, createdTime=Mon Sep 04 20:45:57 CST 2023, time=2023-09-04, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=1073628, encodeId=bf4b10e3628d6, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向:心血管代谢<br>经验分享:一审一个月,2个审稿人,给的意见都很不错,修回编辑直接决定接收了,文章如果比较新颖,故事说的也比较完整还是很有希望的!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1291, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=95512077050, createdName=1321f15a85m, createdTime=Wed Nov 24 20:49:29 CST 2021, time=2021-11-24, status=1, ipAttribution=)]
    2021-03-02 延光星辰

    2020.09.22投稿,一审3个月,催稿问了下,说是前两个审稿人意见有分歧,所以邀请了第三个审稿人;返回大修2个月;2021.02.04再投,目前with editor了,希望能接收,祈祷

    5

    展开5条回复
  8. [GetPortalCommentsPageByObjectIdResponse(id=2195585, encodeId=5f702195585d8, content=审稿速度:3.0 | 投稿命中率:25.0<br>经验分享:3月18日 投稿,到现在 一直是 Manuscript Submitted!什么情况,我看着大家的速度都挺快啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=7b725453206, createdName=ms8000000183026287, createdTime=Wed Mar 27 06:41:54 CST 2024, time=2024-03-27, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2183773, encodeId=0a5a2183e7317, content=不能提供中文的伦理,不懂怎么搞, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b1668197286, createdName=ms6000000741257643, createdTime=Wed Jan 24 23:26:21 CST 2024, time=2024-01-24, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2182073, encodeId=9c2d21820e320, content=审稿速度:1.0<br>偏重的研究方向:代谢内分泌<br>经验分享:1.9号投的稿,已经过去7天了,一直在with editor的状态。想请教各位大佬何时才会under review呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5d4b8504046, createdName=ms8000001820221539, createdTime=Tue Jan 16 21:41:20 CST 2024, time=2024-01-16, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2144472, encodeId=076121444e2ef, content=第一天投稿,第二天under review,第四天with editor。。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=171, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230102/946f899161a14c3dbe77c26d05ba17d8/114975187bd54951beda40eaafd6f34e.jpg, createdBy=59ae5404963, createdName=MedSci_007, createdTime=Sat Jun 24 09:58:02 CST 2023, time=2023-06-24, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2165427, encodeId=86f3216542ea7, content=为什么回顾性研究也邮件让我发provide the Institutional Review Board or ethical review board’s approval/exemption letter,我明明文章中已经提到which waived the requirement for informed consent because of the retrospective nature of this study啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=82, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e43b5476402, createdName=ms4000001768031770, createdTime=Sat Oct 28 16:07:09 CST 2023, time=2023-10-28, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1241105, encodeId=c8d0124110569, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向:心血管;糖尿病<br>经验分享:记录一下,第一个SCI:5月10日投稿的,大约5天内就被under review被送审了。一个月后返回。修稿一个月后,两周就接受啦。审稿速度非常可!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=396, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=35e75613536, createdName=ms5000000174582530, createdTime=Fri Aug 26 09:43:34 CST 2022, time=2022-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=944787, encodeId=ab53944e87d6, content=2020.09.22投稿,一审3个月,催稿问了下,说是前两个审稿人意见有分歧,所以邀请了第三个审稿人;返回大修2个月;2021.02.04再投,目前with editor了,希望能接收,祈祷, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=682, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLFHmdHZlP01VibUiaSUygPr1vfgUOicNUzicicuib25U9FM5WbtwPBfX6diaZbduz72Vjf0KFc8TINLKKvA/132, createdBy=d1062255989, createdName=延光星辰, createdTime=Tue Mar 02 14:31:35 CST 2021, time=2021-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1187926, encodeId=a5d4118e92666, content=审稿速度:2.0<br>偏重的研究方向:心血管<br>经验分享:记录一下第一篇SCI:10/30/2021Submitted, 12/07/2021Revise, 01/04/2022Revise manuscript submitted, 01/13/2022Revise, 01/24/2022Accept<br>稿件处理速度可以,投稿后很快就Under review了,意见回来是major revision,两个审稿人在领域内比较专业,提了一大堆意见,花了近一个月时间才修好稿件,提交后面又经历了两次小修,意见回的很快,最后接收。<br>Revise后提交稿件要求Supplementary文件上传公共数据库并在文中引用,Manuscript里不能带有Supplementary图表的信息。Revise给的时间是3个月,还是很充裕的。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1261, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d5e05514512, createdName=陈呦呦, createdTime=Tue Jan 25 08:40:28 CST 2022, time=2022-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2156082, encodeId=856a215608284, content=为什么 投稿过程老是提示Additional information未完成呢?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=155, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=08398439451, createdName=ms3000001792867707, createdTime=Mon Sep 04 20:45:57 CST 2023, time=2023-09-04, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=1073628, encodeId=bf4b10e3628d6, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向:心血管代谢<br>经验分享:一审一个月,2个审稿人,给的意见都很不错,修回编辑直接决定接收了,文章如果比较新颖,故事说的也比较完整还是很有希望的!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1291, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=95512077050, createdName=1321f15a85m, createdTime=Wed Nov 24 20:49:29 CST 2021, time=2021-11-24, status=1, ipAttribution=)]
    2022-01-25 陈呦呦

    审稿速度:2.0
    偏重的研究方向:心血管
    经验分享:记录一下第一篇SCI:10/30/2021Submitted, 12/07/2021Revise, 01/04/2022Revise manuscript submitted, 01/13/2022Revise, 01/24/2022Accept
    稿件处理速度可以,投稿后很快就Under review了,意见回来是major revision,两个审稿人在领域内比较专业,提了一大堆意见,花了近一个月时间才修好稿件,提交后面又经历了两次小修,意见回的很快,最后接收。
    Revise后提交稿件要求Supplementary文件上传公共数据库并在文中引用,Manuscript里不能带有Supplementary图表的信息。Revise给的时间是3个月,还是很充裕的。

    4

    展开4条回复
  9. [GetPortalCommentsPageByObjectIdResponse(id=2195585, encodeId=5f702195585d8, content=审稿速度:3.0 | 投稿命中率:25.0<br>经验分享:3月18日 投稿,到现在 一直是 Manuscript Submitted!什么情况,我看着大家的速度都挺快啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=7b725453206, createdName=ms8000000183026287, createdTime=Wed Mar 27 06:41:54 CST 2024, time=2024-03-27, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2183773, encodeId=0a5a2183e7317, content=不能提供中文的伦理,不懂怎么搞, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b1668197286, createdName=ms6000000741257643, createdTime=Wed Jan 24 23:26:21 CST 2024, time=2024-01-24, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2182073, encodeId=9c2d21820e320, content=审稿速度:1.0<br>偏重的研究方向:代谢内分泌<br>经验分享:1.9号投的稿,已经过去7天了,一直在with editor的状态。想请教各位大佬何时才会under review呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5d4b8504046, createdName=ms8000001820221539, createdTime=Tue Jan 16 21:41:20 CST 2024, time=2024-01-16, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2144472, encodeId=076121444e2ef, content=第一天投稿,第二天under review,第四天with editor。。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=171, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230102/946f899161a14c3dbe77c26d05ba17d8/114975187bd54951beda40eaafd6f34e.jpg, createdBy=59ae5404963, createdName=MedSci_007, createdTime=Sat Jun 24 09:58:02 CST 2023, time=2023-06-24, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2165427, encodeId=86f3216542ea7, content=为什么回顾性研究也邮件让我发provide the Institutional Review Board or ethical review board’s approval/exemption letter,我明明文章中已经提到which waived the requirement for informed consent because of the retrospective nature of this study啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=82, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e43b5476402, createdName=ms4000001768031770, createdTime=Sat Oct 28 16:07:09 CST 2023, time=2023-10-28, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1241105, encodeId=c8d0124110569, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向:心血管;糖尿病<br>经验分享:记录一下,第一个SCI:5月10日投稿的,大约5天内就被under review被送审了。一个月后返回。修稿一个月后,两周就接受啦。审稿速度非常可!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=396, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=35e75613536, createdName=ms5000000174582530, createdTime=Fri Aug 26 09:43:34 CST 2022, time=2022-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=944787, encodeId=ab53944e87d6, content=2020.09.22投稿,一审3个月,催稿问了下,说是前两个审稿人意见有分歧,所以邀请了第三个审稿人;返回大修2个月;2021.02.04再投,目前with editor了,希望能接收,祈祷, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=682, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLFHmdHZlP01VibUiaSUygPr1vfgUOicNUzicicuib25U9FM5WbtwPBfX6diaZbduz72Vjf0KFc8TINLKKvA/132, createdBy=d1062255989, createdName=延光星辰, createdTime=Tue Mar 02 14:31:35 CST 2021, time=2021-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1187926, encodeId=a5d4118e92666, content=审稿速度:2.0<br>偏重的研究方向:心血管<br>经验分享:记录一下第一篇SCI:10/30/2021Submitted, 12/07/2021Revise, 01/04/2022Revise manuscript submitted, 01/13/2022Revise, 01/24/2022Accept<br>稿件处理速度可以,投稿后很快就Under review了,意见回来是major revision,两个审稿人在领域内比较专业,提了一大堆意见,花了近一个月时间才修好稿件,提交后面又经历了两次小修,意见回的很快,最后接收。<br>Revise后提交稿件要求Supplementary文件上传公共数据库并在文中引用,Manuscript里不能带有Supplementary图表的信息。Revise给的时间是3个月,还是很充裕的。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1261, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d5e05514512, createdName=陈呦呦, createdTime=Tue Jan 25 08:40:28 CST 2022, time=2022-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2156082, encodeId=856a215608284, content=为什么 投稿过程老是提示Additional information未完成呢?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=155, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=08398439451, createdName=ms3000001792867707, createdTime=Mon Sep 04 20:45:57 CST 2023, time=2023-09-04, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=1073628, encodeId=bf4b10e3628d6, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向:心血管代谢<br>经验分享:一审一个月,2个审稿人,给的意见都很不错,修回编辑直接决定接收了,文章如果比较新颖,故事说的也比较完整还是很有希望的!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1291, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=95512077050, createdName=1321f15a85m, createdTime=Wed Nov 24 20:49:29 CST 2021, time=2021-11-24, status=1, ipAttribution=)]
    2023-09-04 ms3000001792867707 来自江苏省

    为什么 投稿过程老是提示Additional information未完成呢?

    0

  10. [GetPortalCommentsPageByObjectIdResponse(id=2195585, encodeId=5f702195585d8, content=审稿速度:3.0 | 投稿命中率:25.0<br>经验分享:3月18日 投稿,到现在 一直是 Manuscript Submitted!什么情况,我看着大家的速度都挺快啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=7b725453206, createdName=ms8000000183026287, createdTime=Wed Mar 27 06:41:54 CST 2024, time=2024-03-27, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2183773, encodeId=0a5a2183e7317, content=不能提供中文的伦理,不懂怎么搞, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b1668197286, createdName=ms6000000741257643, createdTime=Wed Jan 24 23:26:21 CST 2024, time=2024-01-24, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2182073, encodeId=9c2d21820e320, content=审稿速度:1.0<br>偏重的研究方向:代谢内分泌<br>经验分享:1.9号投的稿,已经过去7天了,一直在with editor的状态。想请教各位大佬何时才会under review呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5d4b8504046, createdName=ms8000001820221539, createdTime=Tue Jan 16 21:41:20 CST 2024, time=2024-01-16, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2144472, encodeId=076121444e2ef, content=第一天投稿,第二天under review,第四天with editor。。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=171, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230102/946f899161a14c3dbe77c26d05ba17d8/114975187bd54951beda40eaafd6f34e.jpg, createdBy=59ae5404963, createdName=MedSci_007, createdTime=Sat Jun 24 09:58:02 CST 2023, time=2023-06-24, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2165427, encodeId=86f3216542ea7, content=为什么回顾性研究也邮件让我发provide the Institutional Review Board or ethical review board’s approval/exemption letter,我明明文章中已经提到which waived the requirement for informed consent because of the retrospective nature of this study啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=82, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e43b5476402, createdName=ms4000001768031770, createdTime=Sat Oct 28 16:07:09 CST 2023, time=2023-10-28, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1241105, encodeId=c8d0124110569, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向:心血管;糖尿病<br>经验分享:记录一下,第一个SCI:5月10日投稿的,大约5天内就被under review被送审了。一个月后返回。修稿一个月后,两周就接受啦。审稿速度非常可!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=396, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=35e75613536, createdName=ms5000000174582530, createdTime=Fri Aug 26 09:43:34 CST 2022, time=2022-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=944787, encodeId=ab53944e87d6, content=2020.09.22投稿,一审3个月,催稿问了下,说是前两个审稿人意见有分歧,所以邀请了第三个审稿人;返回大修2个月;2021.02.04再投,目前with editor了,希望能接收,祈祷, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=682, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLFHmdHZlP01VibUiaSUygPr1vfgUOicNUzicicuib25U9FM5WbtwPBfX6diaZbduz72Vjf0KFc8TINLKKvA/132, createdBy=d1062255989, createdName=延光星辰, createdTime=Tue Mar 02 14:31:35 CST 2021, time=2021-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1187926, encodeId=a5d4118e92666, content=审稿速度:2.0<br>偏重的研究方向:心血管<br>经验分享:记录一下第一篇SCI:10/30/2021Submitted, 12/07/2021Revise, 01/04/2022Revise manuscript submitted, 01/13/2022Revise, 01/24/2022Accept<br>稿件处理速度可以,投稿后很快就Under review了,意见回来是major revision,两个审稿人在领域内比较专业,提了一大堆意见,花了近一个月时间才修好稿件,提交后面又经历了两次小修,意见回的很快,最后接收。<br>Revise后提交稿件要求Supplementary文件上传公共数据库并在文中引用,Manuscript里不能带有Supplementary图表的信息。Revise给的时间是3个月,还是很充裕的。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1261, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d5e05514512, createdName=陈呦呦, createdTime=Tue Jan 25 08:40:28 CST 2022, time=2022-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2156082, encodeId=856a215608284, content=为什么 投稿过程老是提示Additional information未完成呢?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=155, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=08398439451, createdName=ms3000001792867707, createdTime=Mon Sep 04 20:45:57 CST 2023, time=2023-09-04, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=1073628, encodeId=bf4b10e3628d6, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向:心血管代谢<br>经验分享:一审一个月,2个审稿人,给的意见都很不错,修回编辑直接决定接收了,文章如果比较新颖,故事说的也比较完整还是很有希望的!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1291, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=95512077050, createdName=1321f15a85m, createdTime=Wed Nov 24 20:49:29 CST 2021, time=2021-11-24, status=1, ipAttribution=)]
    2021-11-24 1321f15a85m

    审稿速度:1.0 | 投稿命中率:50.0
    偏重的研究方向:心血管代谢
    经验分享:一审一个月,2个审稿人,给的意见都很不错,修回编辑直接决定接收了,文章如果比较新颖,故事说的也比较完整还是很有希望的!

    2

    展开2条回复
共173条页码: 1/18页10条/页
分享您的投稿经验,提升MI经验值,获取更多积分